Effects of Oral Supplementation with Docosahexaenoic Acid (DHA) plus Antioxidants in Pseudoexfoliative Glaucoma: A 6-Month Open-Label Randomized Trial
Purpose. To assess the effects of antioxidant oral supplementation based on docosahexaenoic acid (DHA) in pseudoexfoliative (PEX) glaucoma. Patients and Methods. A prospective 6-month open-label randomized controlled trial was conducted in patients with PEX glaucoma and adequate intraocular pressure...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2018/8259371 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850236237109002240 |
|---|---|
| author | Stéphanie Romeo Villadóniga Elena Rodríguez García Olatz Sagastagoia Epelde M. Dolores Álvarez Díaz Joan Carles Domingo Pedrol |
| author_facet | Stéphanie Romeo Villadóniga Elena Rodríguez García Olatz Sagastagoia Epelde M. Dolores Álvarez Díaz Joan Carles Domingo Pedrol |
| author_sort | Stéphanie Romeo Villadóniga |
| collection | DOAJ |
| description | Purpose. To assess the effects of antioxidant oral supplementation based on docosahexaenoic acid (DHA) in pseudoexfoliative (PEX) glaucoma. Patients and Methods. A prospective 6-month open-label randomized controlled trial was conducted in patients with PEX glaucoma and adequate intraocular pressure (IOP) control. Patients in the DHA group received a high-rich DHA (1 g) nutraceutical formulation. Ophthalmological examination, DHA erythrocyte membrane content (% total fatty acids), plasma total antioxidant capacity (TAC), plasma malondialdehyde (MDA), and plasma IL-6 levels were assessed. Results. Forty-seven patients (DHA group 23, controls 24; mean age 70.3 years) were included. In the DHA group, the mean IOP in the right eye decreased from 14.7 [3.3] mmHg at baseline to 12.1 [1.5] mmHg at 6 months (P=0.01). In the left eye, IOP decreased from 15.1 [3.3] mmHg at baseline to 12.2 [2.4] mmHg at 6 months (P=0.007). DHA erythrocyte content increased in the DHA group, with significant differences versus controls at 3 months and 6 months (8.1% [0.9] vs. 4.4% [0.7]; P<0.0001). At 6 months and in the DHA group only, TAC levels as compared with baseline increased significantly (919.7 [117.9] vs. 856.9 [180.3] µM copper-reducing equivalents; P=0.01), and both MDA (4.4 [0.8] vs. 5.2 [1.1] nmol/mL; P = 0.02) and IL-6 (2.8 [1.3] vs. 4.7 [2.3] pg/mL; P=0.006) levels were lower than in controls. Conclusions. Targeting pathophysiology mechanisms of PEX glaucoma by reducing oxidative stress and inflammation with a high-rich DHA supplement might be an attractive therapeutic approach. Despite the short duration of treatment, decrease in IOP supports the clinical significance of DHA supplementation. |
| format | Article |
| id | doaj-art-152bf7adbb5c4bda9d421ce3758ccc96 |
| institution | OA Journals |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-152bf7adbb5c4bda9d421ce3758ccc962025-08-20T02:02:01ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/82593718259371Effects of Oral Supplementation with Docosahexaenoic Acid (DHA) plus Antioxidants in Pseudoexfoliative Glaucoma: A 6-Month Open-Label Randomized TrialStéphanie Romeo Villadóniga0Elena Rodríguez García1Olatz Sagastagoia Epelde2M. Dolores Álvarez Díaz3Joan Carles Domingo Pedrol4Service of Ophthalmology, Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, SpainService of Ophthalmology, Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, SpainClinical Analysis Laboratory, Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, SpainService of Ophthalmology, Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, SpainDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, Barcelona, SpainPurpose. To assess the effects of antioxidant oral supplementation based on docosahexaenoic acid (DHA) in pseudoexfoliative (PEX) glaucoma. Patients and Methods. A prospective 6-month open-label randomized controlled trial was conducted in patients with PEX glaucoma and adequate intraocular pressure (IOP) control. Patients in the DHA group received a high-rich DHA (1 g) nutraceutical formulation. Ophthalmological examination, DHA erythrocyte membrane content (% total fatty acids), plasma total antioxidant capacity (TAC), plasma malondialdehyde (MDA), and plasma IL-6 levels were assessed. Results. Forty-seven patients (DHA group 23, controls 24; mean age 70.3 years) were included. In the DHA group, the mean IOP in the right eye decreased from 14.7 [3.3] mmHg at baseline to 12.1 [1.5] mmHg at 6 months (P=0.01). In the left eye, IOP decreased from 15.1 [3.3] mmHg at baseline to 12.2 [2.4] mmHg at 6 months (P=0.007). DHA erythrocyte content increased in the DHA group, with significant differences versus controls at 3 months and 6 months (8.1% [0.9] vs. 4.4% [0.7]; P<0.0001). At 6 months and in the DHA group only, TAC levels as compared with baseline increased significantly (919.7 [117.9] vs. 856.9 [180.3] µM copper-reducing equivalents; P=0.01), and both MDA (4.4 [0.8] vs. 5.2 [1.1] nmol/mL; P = 0.02) and IL-6 (2.8 [1.3] vs. 4.7 [2.3] pg/mL; P=0.006) levels were lower than in controls. Conclusions. Targeting pathophysiology mechanisms of PEX glaucoma by reducing oxidative stress and inflammation with a high-rich DHA supplement might be an attractive therapeutic approach. Despite the short duration of treatment, decrease in IOP supports the clinical significance of DHA supplementation.http://dx.doi.org/10.1155/2018/8259371 |
| spellingShingle | Stéphanie Romeo Villadóniga Elena Rodríguez García Olatz Sagastagoia Epelde M. Dolores Álvarez Díaz Joan Carles Domingo Pedrol Effects of Oral Supplementation with Docosahexaenoic Acid (DHA) plus Antioxidants in Pseudoexfoliative Glaucoma: A 6-Month Open-Label Randomized Trial Journal of Ophthalmology |
| title | Effects of Oral Supplementation with Docosahexaenoic Acid (DHA) plus Antioxidants in Pseudoexfoliative Glaucoma: A 6-Month Open-Label Randomized Trial |
| title_full | Effects of Oral Supplementation with Docosahexaenoic Acid (DHA) plus Antioxidants in Pseudoexfoliative Glaucoma: A 6-Month Open-Label Randomized Trial |
| title_fullStr | Effects of Oral Supplementation with Docosahexaenoic Acid (DHA) plus Antioxidants in Pseudoexfoliative Glaucoma: A 6-Month Open-Label Randomized Trial |
| title_full_unstemmed | Effects of Oral Supplementation with Docosahexaenoic Acid (DHA) plus Antioxidants in Pseudoexfoliative Glaucoma: A 6-Month Open-Label Randomized Trial |
| title_short | Effects of Oral Supplementation with Docosahexaenoic Acid (DHA) plus Antioxidants in Pseudoexfoliative Glaucoma: A 6-Month Open-Label Randomized Trial |
| title_sort | effects of oral supplementation with docosahexaenoic acid dha plus antioxidants in pseudoexfoliative glaucoma a 6 month open label randomized trial |
| url | http://dx.doi.org/10.1155/2018/8259371 |
| work_keys_str_mv | AT stephanieromeovilladoniga effectsoforalsupplementationwithdocosahexaenoicaciddhaplusantioxidantsinpseudoexfoliativeglaucomaa6monthopenlabelrandomizedtrial AT elenarodriguezgarcia effectsoforalsupplementationwithdocosahexaenoicaciddhaplusantioxidantsinpseudoexfoliativeglaucomaa6monthopenlabelrandomizedtrial AT olatzsagastagoiaepelde effectsoforalsupplementationwithdocosahexaenoicaciddhaplusantioxidantsinpseudoexfoliativeglaucomaa6monthopenlabelrandomizedtrial AT mdoloresalvarezdiaz effectsoforalsupplementationwithdocosahexaenoicaciddhaplusantioxidantsinpseudoexfoliativeglaucomaa6monthopenlabelrandomizedtrial AT joancarlesdomingopedrol effectsoforalsupplementationwithdocosahexaenoicaciddhaplusantioxidantsinpseudoexfoliativeglaucomaa6monthopenlabelrandomizedtrial |